↓ Skip to main content

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
27 X users
patent
3 patents

Readers on

mendeley
106 Mendeley